Findings from statin trials previously suggested LDL-C lowering through inhibition of HMG-coA reductase is associated with a reduced risk of ischemic but potentially increased risk of hemorrhagic stroke [30–32]. The gene discussed is HMGCR; the disease is hemorrhagic stroke.